iOrganBio, an innovator in intelligent cell manufacturing that is redefining how human cells are engineered and reliably produced at scale for research and therapeutic applications, including FDA-aligned New Approach Methodologies (NAMs), today announced the appointment of Zhiping Pang, M.D., Ph.D., to its Scientific Advisory Board.
Dr. Pang is one of the leading experts in human neuron biology, synaptic function, and the molecular mechanisms underlying neuropsychiatric and metabolic disorders, with more than 140 publications in top journals including Nature, Science, Nature Neuroscience, and Nature Metabolism. He is the Henry Rutgers Professor of NeuroMetabolism and Professor of Neuroscience and Cell Biology at Rutgers Robert Wood Johnson Medical School, and the Director of the Center for NeuroMetabolism at Rutgers Health.
This appointment strengthens the scientific breadth advising iOrganBio as the field moves toward more human-relevant, non-animal systems. Dr. Pang's expertise complements iOrganBio's mission to advance human cell and organoid production using its AI-powered platform, CellForge™. The platform uses AI and automation to guide cell development and make real-time adjustments aligned with defined biological profiles, enabling consistent, scalable manufacturing of cells and organoids for in vitro modeling and cell therapies.
At the core of CellForge is iOrganBio's functional human CellAtlas™, a comprehensive reference built from single-cell and multi-omics data that provides the digital blueprints for each cell type. This smart, closed-loop process delivers the accuracy, efficiency, and quality partners need to turn scientific ideas into breakthroughs, accelerating disease modeling, regenerative medicine, and drug development.
The appointment of Dr. Pang bolsters iOrganBio's position as a leader in AI-enabled, scalable, human cell and organoid production. As the industry increasingly adopts New Approach Methodologies that reduce reliance on animal testing, having experts like Dr. Pang on the advisory board is critical for guiding the scientific direction of the company. For more information, visit iOrgan.Bio or follow on LinkedIn.
This announcement underscores the growing importance of combining advanced biology with artificial intelligence to meet the demands of modern biomedical research. By integrating Dr. Pang's deep knowledge of human neuron biology and synaptic function, iOrganBio is poised to enhance its capabilities in modeling neurological and metabolic disorders, potentially leading to more effective therapies.
